| Epigenetic therapy for ovarian cancer: promise and progress S Moufarrij, M Dandapani, E Arthofer, S Gomez, A Srivastava, ... Clinical epigenetics 11 (1), 1-11, 2019 | 242 | 2019 |
| Combining epigenetic and immune therapy to overcome cancer resistance S Gomez, T Tabernacki, J Kobyra, P Roberts, KB Chiappinelli Seminars in cancer biology 65, 99-113, 2020 | 123 | 2020 |
| Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer S Moufarrij, A Srivastava, S Gomez, M Hadley, E Palmer, PT Austin, ... Scientific Reports 10 (1), 3470, 2020 | 86 | 2020 |
| Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a TP53-Dependent Manner JI McDonald, N Diab, E Arthofer, M Hadley, T Kanholm, U Rentia, ... Cancer research 81 (20), 5176-5189, 2021 | 23 | 2021 |
| Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer S Gomez, OL Cox, RR Walker III, U Rentia, M Hadley, E Arthofer, N Diab, ... Journal for Immunotherapy of Cancer 10 (11), 2022 | 20 | 2022 |
| A Trypanosoma brucei ORFeome-based gain-of-function library identifies genes that promote survival during melarsoprol treatment MK Carter, S Gomez, S Gritz, S Larson, E Silva-Herzog, HS Kim, D Schulz, ... Msphere 5 (5), 10.1128/msphere. 00769-20, 2020 | 13 | 2020 |
